Connect Biopharma Holdings Ltd
CNTB2.400USD
+0.130+5.73%
Market hours （ET）Quotes delayed by 15 min
133.89MMarket Cap
LossP/E TTM
More Details of Connect Biopharma Holdings Ltd Company
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Connect Biopharma Holdings Ltd Info
Ticker SymbolCNTB
Company nameConnect Biopharma Holdings Ltd
IPO dateMar 19, 2021
CEOQuart (Barry D)
Number of employees62
Security typeOrdinary Share
Fiscal year-endMar 19
Address3580 Carmel Mountain Road, Suite 200
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92130
Phone18587271040
Websitehttps://www.connectbiopharm.com
Ticker SymbolCNTB
IPO dateMar 19, 2021
CEOQuart (Barry D)
Company Executives of Connect Biopharma Holdings Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
131.89K
--
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
80.00K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
10.00K
--
Ms. Lisa Peraza
Ms. Lisa Peraza
Vice President - Finance
Vice President - Finance
--
--
Kimberly Kimberly
Kimberly Kimberly
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Dr. Lei Sun, Ph.D.
Dr. Lei Sun, Ph.D.
Vice President - Biologics and Head of CMC
Vice President - Biologics and Head of CMC
--
--
Mr. Jeff Cohn, J.D.
Mr. Jeff Cohn, J.D.
General Counsel and Corporate Secretary
General Counsel and Corporate Secretary
--
--
Mr. Raul Collazo, Ph.D.
Mr. Raul Collazo, Ph.D.
Vice President - Global Medical Affairs
Vice President - Global Medical Affairs
--
--
Mr. David L. Szekeres
Mr. David L. Szekeres
President
President
--
--
Dr. Kan Chen, Ph.D.
Dr. Kan Chen, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
131.89K
--
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
80.00K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
10.00K
--
Ms. Lisa Peraza
Ms. Lisa Peraza
Vice President - Finance
Vice President - Finance
--
--
Kimberly Kimberly
Kimberly Kimberly
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Dr. Lei Sun, Ph.D.
Dr. Lei Sun, Ph.D.
Vice President - Biologics and Head of CMC
Vice President - Biologics and Head of CMC
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Panacea Venture
21.47%
BioFortune Inc
11.02%
Shanghai Minhui Enterprise Management Consulting Partnership
9.49%
Wei (Zheng)
9.35%
Qiming Venture Partners
8.66%
Other
40.02%
Shareholders
Shareholders
Proportion
Panacea Venture
21.47%
BioFortune Inc
11.02%
Shanghai Minhui Enterprise Management Consulting Partnership
9.49%
Wei (Zheng)
9.35%
Qiming Venture Partners
8.66%
Other
40.02%
Shareholder Types
Shareholders
Proportion
Venture Capital
36.14%
Corporation
29.03%
Individual Investor
10.12%
Investment Advisor
2.57%
Hedge Fund
0.28%
Investment Advisor/Hedge Fund
0.15%
Other
21.72%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
39
23.82M
44.06%
--
2025Q3
44
23.82M
51.87%
-292.56K
2025Q2
43
24.11M
49.99%
-302.92K
2025Q1
42
24.43M
50.72%
-3.65M
2024Q4
48
24.78M
51.96%
+236.30K
2024Q3
55
24.55M
53.49%
-34.12K
2024Q2
62
24.58M
57.85%
+441.50K
2024Q1
65
24.14M
48.89%
-2.80M
2023Q4
72
21.31M
33.82%
+215.31K
2023Q3
80
21.09M
40.53%
-286.24K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Panacea Venture
13.95M
25.04%
+540.00K
+4.03%
Jul 21, 2025
BioFortune Inc
6.16M
11.05%
--
--
Mar 21, 2025
Shanghai Minhui Enterprise Management Consulting Partnership
5.31M
9.52%
--
--
Mar 21, 2025
Wei (Zheng)
5.93M
10.64%
--
--
Mar 21, 2025
Qiming Venture Partners
4.84M
8.69%
--
--
Mar 21, 2025
Advantech Capital II L.P.
4.76M
8.55%
--
--
Mar 21, 2025
Lilly Asia Ventures
3.34M
5.99%
--
--
Mar 21, 2025
BML Capital Management LLC
1.82M
3.27%
-271.67K
-12.98%
Jun 30, 2025
Szekeres (David Leslie)
160.87K
0.29%
+160.87K
--
Mar 21, 2025
Renaissance Technologies LLC
143.70K
0.26%
+28.90K
+25.17%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
SPDR Portfolio Emerging Markets ETF
0%
SPDR Portfolio Emerging Markets ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Connect Biopharma Holdings Ltd?
The top five shareholders of Connect Biopharma Holdings Ltd are:
Panacea Venture holds 13.95M shares, accounting for 25.04% of the total shares.
BioFortune Inc holds 6.16M shares, accounting for 11.05% of the total shares.
Shanghai Minhui Enterprise Management Consulting Partnership holds 5.31M shares, accounting for 9.52% of the total shares.
Wei (Zheng) holds 5.93M shares, accounting for 10.64% of the total shares.
Qiming Venture Partners holds 4.84M shares, accounting for 8.69% of the total shares.
Panacea Venture holds 13.95M shares, accounting for 25.04% of the total shares.
BioFortune Inc holds 6.16M shares, accounting for 11.05% of the total shares.
Shanghai Minhui Enterprise Management Consulting Partnership holds 5.31M shares, accounting for 9.52% of the total shares.
Wei (Zheng) holds 5.93M shares, accounting for 10.64% of the total shares.
Qiming Venture Partners holds 4.84M shares, accounting for 8.69% of the total shares.
What are the top three shareholder types of Connect Biopharma Holdings Ltd?
The top three shareholder types of Connect Biopharma Holdings Ltd are:
Panacea Venture
BioFortune Inc
Shanghai Minhui Enterprise Management Consulting Partnership
Panacea Venture
BioFortune Inc
Shanghai Minhui Enterprise Management Consulting Partnership
How many institutions hold shares of Connect Biopharma Holdings Ltd (CNTB)?
As of 2025Q4, 39 institutions hold shares of Connect Biopharma Holdings Ltd, with a combined market value of approximately 23.82M, accounting for 44.06% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -7.81%.
What is the biggest source of revenue for Connect Biopharma Holdings Ltd?
In --, the -- business generated the highest revenue for Connect Biopharma Holdings Ltd, amounting to -- and accounting for --% of total revenue.
